A. Mendelsohn

发表

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Yang Zhao, T. Brodtkorb, X. Jia, 2020, PharmacoEconomics - Open.

Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

Yang Zhao, S. Feldman, A. Armstrong, 2020, The Journal of dermatological treatment.

PBI34 PREDICTIVE VALUE OF EARLY PASI RESPONSE TO TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

Yang Zhao, A. Gottlieb, S. Feldman, 2019, Value in Health.

Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data

Jashin J. Wu, B. Glick, Xue Song, 2021, Journal of medical economics.